INTRODUCTION {#sec0005}
============

Urinary bladder cancer is common, with more than 75,000 cases expected and over 16,000 deaths in the United States in 2016 \[[@ref001]\]. Most cases (70%) present as superficial, non-muscle invasive disease. One unique feature in the treatment of superficial urinary bladder cancer is the ability to deliver medical therapy directly to bladder tumors via a urinary catheter. This approach may also limit systemic drug exposure minimizing the toxic impact of therapy. Intravesical bacillus Calmette-Guérin (BCG), administered into the bladder by routine urinary catheterization, has been a standard approach to non-muscle invasive bladder cancer for decades. Despite BCG treatment, recurrent and progressive disease leading to cystectomy or metastatic disease is common \[[@ref002]\].

Recently, the use of gold nanorods (nanotechnology) has become an area of increased research investigation, including therapeutic applications \[[@ref003]\]. However, with systemic delivery of nanoparticles, concerns about hepatic and renal clearance have been raised \[[@ref005]\]. In seeking a differentially-expressed cell surface tumor marker in bladder cancer, the epidermal growth factor receptor (EGFR), which is frequently over-expressed on luminal surface of bladder cancer cells \[[@ref007]\], as opposed to the normal urothelium, appears to be a good therapeutic targeting candidate. Based on the current clinical use of fiber-optic cystoscopes \[[@ref010]\], the use of novel intravesical nanoparticle-directed therapy in conjunction with photothermal laser irradiation via a fiber-optic cystoscope, represents a clinically feasible treatment approach in patients with superficial bladder cancer. This would not replace the use of current cystoscopic debulking procedures, but rather augment these by using this approach after such procedures to treat any residual microscopic disease remaining. In a previous study \[[@ref011]\], we described the preparation of Conjugated gold NanoRods (CNR) with addition of an anti-EGFR antibody and its application *in vitro* using the HTB9 bladder cancer cell model. In this study, we examine the safety and efficacy of EGFR-directed nanoparticle thermal ablation therapy *in vivo* using an orthotopic xenograft mouse model. T24 human cells were selected based on their expression of EGFR \[[@ref012]\] and suitability for orthotopic implantation, which was critical to these intravesical experiments. While the eventual clinical application would provide laser delivery via a cystoscopic means, we use external delivery in this model, as NIR has adequate tissue penetration to reach all aspects of the murine bladder (reviewed herein \[[@ref013]\]). We have previously developed this orthotopic model of bladder cancer with T24 human bladder cancer cells, using a bioluminescent response endpoint, for which a response was well correlated to pathologic response \[[@ref012]\].

MATERIALS AND METHODS {#sec0010}
=====================

Materials, laser and cells {#sec0015}
--------------------------

Gold nanorods and CNR were prepared by the method described before \[[@ref011]\]. An 808 nm diode laser (DILAS MINI 808-50/400) was purchased from Dilas Diode Laser Inc. (Tucson, AZ). T24 cells were obtained from ATCC (Manassas, VA). T24 cells with luciferase labeling were prepared following the previously reported method \[[@ref012]\]. Cell line authentication was done by UCCC DNA Sequence & Analyses Core, using ABI Identifiler kit. The loci tested are the following: D3S1358, vWA, FGA, Amelogenin, D8S1179, D21S11, D18S51, D5S818, D13S137, D7S820, CSF1PO, D16S539, THO1, TPOX, D2S1338, and D19S433. MB49 murine bladder cancer plus, A549 and H520 human lung cancer cells were obtained via the UCCC tissue culture core.

Animals {#sec0020}
-------

Female athymic nude (nu/nu) mice (6--8 weeks) were obtained from the Animal Production Area of the National Cancer Institute (Frederick, MD) in an approved protocol.

In vitro studies {#sec0025}
----------------

To study the binding specificity of CNR, we tested a pair of well-published model of EGFR expression, using EGFR-positive (A549) and EGFR-negative (H520) human lung cancer cell lines. In order to distinguish EGFR-positive and EGFR-negative cells by fluorescent microscope, H520-NLR cells were developed by transducing NucLight Red lentivirus (ESSEN BioScience). The stable cell line expresses nuclear restricted red fluorescent protein (excitation 588 nm and emission 633 nm). CNR were visualized using DyLight labelled secondary antibody (488 excitation peak 493 nm and emission peak 518 nm) against the C-225 (Erbitux (2 mg/mL) manufactured by ImClone LLC and Distributed by Bristol-Myers Squibb), to detect the CNR.

A mixture of A549/H520-NLR cells (1×10^4^ cells/well) were seeded in 8-well chamber slides. The, cells incubated with CNR (8×10^10^ particles per mL) for 2 hours. Post CNR treatment, the cells were washed twice with 400*μ*L DPBS to remove unbound CNR then probed with Dylight labelled donkey anti-human antibody for 1 hour and washed three times with DPBS. The cells with red nuclei (H520-NLR) were visualized separately from the CNR-bound A549 dells with green fluorescent ([Fig. 1A](#blc-3-blc170096-g001){ref-type="fig"}).

![*In vitro* testing. EGFR-negative H520 (NucLight red) were mixed with EGFR-positive A549 cells ([Fig. 1A](#blc-3-blc170096-g001){ref-type="fig"}). The left panel shows bright field images of all cells, the middle panel shows green fluorescence of the CNR binding the EGFR-positive A549 cells (Donkey anti human Dylight labelled secondary antibody) and the Right panel shows the Red fluorescing H520 cells (location indicated by the blue arrows in each panel). MB49 bladder cancer cells were treated with CNR and laser at increasing exposure duration with cell survival assessed by MTT assay. Standard deviation is shown ([Fig. 1B](#blc-3-blc170096-g001){ref-type="fig"}). MB49 cells were incubated with the guiding C-225 antibody and the CNR construct to assess any inherit toxicity from the CNR in the absence of laser. An MTT assay was performed after 5 days ([Fig. 1C](#blc-3-blc170096-g001){ref-type="fig"}).](blc-3-blc170096-g001){#blc-3-blc170096-g001}

MB49 bladder cancer cells were trypsinized, neutralized and washed twice in DPBS. 100*μ*L of cells (6×10^7^/ml) were incubated with 12*μ*L CNR (8×10^11^ particles/ml) for 2 hours, washed once with 1 ml medium (OptiMEM with 3.75% FCS), centrifuged to remove supernatant and washed again with DPBS. The cells were then suspended in 200*μ*L DPBS. Using U-bottom 96 well plate, 20*μ*L of cells were place in each well with laser treatment at different time exposure. Immediately post laser treatment, cells were diluted in medium and MTT assay (Promega Corporation, Madison,WI, USA CellTiter AQueousOne Solution Cell Proliferation Assay) was used for cell viability assessment ([Fig. 1B](#blc-3-blc170096-g001){ref-type="fig"}). To test for inherent toxicity, MB49 cells incubated with comparable levels of C-225 (1 ng/mL) and CNR for two hours, with MTT performed 5 days post treatment ([Fig. 1C](#blc-3-blc170096-g001){ref-type="fig"}).

Orthotopic implantation {#sec0030}
-----------------------

The orthotopic implantation procedure is similar to the one used in our previous study \[[@ref012]\]. Briefly, the bladder was washed with phosphate buffered saline (PBS) and scratched with the catheter tip before instilling 100*μ*L of 1.5×10^6^ T24-Luc cells via a small catheter. The urethra was temporarily closed with a single, sterile suture at the distal portion of the urethra thus retaining the cells in the bladder for 3 hours. Xenograft implantation was confirmed by the presence of bioluminescence activity 7 days after cell implantation before subsequent nanorod and/or NIR light treatments.

Bioluminescence measurement {#sec0035}
---------------------------

For bioluminescent assessment each mouse received 150 mg luciferin/kg body weight via an intraperitoneal injection. Imaging of the mice was then conducted in anesthetized conditions with the IVIS^®^ Imaging System (MA, USA). The bioluminescent activity was quantified by software provided by Xenogen Corp. (Alameda, CA). Due to the very small size of the tumors, bioluminescent response is the primary endpoint. We have used this endpoint in previous work with an orthotopic model of bladder cancer \[[@ref012]\] and it is a more sensitive endpoint than pathologic assessment due to the very small size of the xenograft tumors.

In vivo treatment with nanorods and NIR light {#sec0040}
---------------------------------------------

One week after cell instillation, bioluminescence activity was measured and used to distribute the mice into balanced treatment and control groups. PBS, Naked gold NanoRods (NNR), C225 (Anti-EGFR antibody), and CNR were instilled into the bladders of corresponding mouse experimental groups, following a similar procedure as described above for cancer cell instillation. Nanorods were diluted (1 : 5 to 1 : 10) from original production concentration to maintain a uniform concentration as determined by the optical density. This intravesical instillation was maintained in the bladder for two hours for each treatment via a temporary retention suture in the distal urethra. Next, the bladder was gently washed twice with cold PBS to remove non-specifically bound nanorods. The laser was carefully directed to the skin surface of the murine pelvis with the guidance of a visible in-fiber pilot light. The mice were treated once per week for four weeks in this manner to test the treatment efficacy and tolerance with weekly monitoring by the IVIS^®^ Imaging System for six weeks. To determine the laser dosing regimen, control mice without tumor cell instillation were treated with laser power densities ranging from 2.1 to 5.3 W/cm^2^, over exposure times of 15 to 30 seconds at a fixed distance from the tip of laser fiber to the skin surface (5.0 cm), and under close observation.

Histopathological procedures and analysis {#sec0045}
-----------------------------------------

After 1-week of treatment, mice were sacrificed and tumors collected. Histological preparations were performed by the Prostate Diagnostic Laboratory, University of Colorado Anschutz Medical Campus. Freshly dissected tissues were bisected, fixed in 10% buffered formalin and embedded in paraffin. Five micron thick paraffin sections were deparaffinized, antigens unmasked and immunohistochemically stained for Ki-67 (Neomarkers/Thermo Scientific, Waltham, MA; rabbit monoclonal SP6; cat\# RM-9106-SO; dilution 1 : 300 in TBST + 1% BSA w/v) and cleaved Caspase 3 (Cell Signaling, Danvers, MA; rabbit polyclonal; cat\#: 9661, 1 : 1000 in TBST + 1% BSA w/v). Antigens were revealed in pH 9.5 BORG solution (Biocare Medical, Concord, CA) for 5 minutes at 125°C (22 psi; Decloaking chamber, Biocare) with a 10 minute ambient cool down. Immunodetection was performed on the autostainer (Benchmark XT; Ventana Medical Systems, Tucson, AZ) at an operating temperature of 37°C. Both primary antibodies were incubated for 32 minutes and detected with a modified I-VIEW DAB (Ventana) detection kit. The I-VIEW secondary antibody was replaced with a species specific polymer (Rabbit ImmPress; Full Strength; Vector Labs, Burlingame, CA; 8 minutes) and streptavidin-horseradish peroxidase was replaced with diluted Rabbit ImmPress (1 : 2 dilution in PBS pH 7.6; 8 minutes). All sections were counterstained in Harris hematoxylin for 2 minutes, blued in 1% ammonium hydroxide (v/v), dehydrated in graded alcohols, cleared in xylene and coverglass mounted using synthetic resin. Stains were performed by a certified histotechnologist (author EES) and the slides were reviewed by a certified pathologist (author FGLR). The pathologic evaluation of urinary bladder specimens was performed blindly to confirm the presence or absence of tumor and then compared with their corresponding bioluminescent measurements.

Statistics {#sec0050}
----------

The results are shown as the mean±standard error of the mean. The data were analyzed by single factor analysis of variance followed by the *post hoc Tukey* tests. Two-sided independent and paired *t*-tests were also performed where indicated. A significance level of *P* \< 0.05 was chosen. SPSS 22.0 (IBM) software was used for all statistical tests.

RESULTS {#sec0055}
=======

In vitro studies {#sec0060}
----------------

Using well established models of EGFR expression in lung cancer, [Fig. 1](#blc-3-blc170096-g001){ref-type="fig"} demonstrates the specificity of the CNR binding to only EGFR-positive cells. The EGFR-negative H520 cells do not show any CNR binding, while the EGFR-positive A549 cells demonstrate a high level of CNR binding ([Fig. 1](#blc-3-blc170096-g001){ref-type="fig"}). These data demonstrate the generalizability of this approach to any EGFR-expressing model of cancer, as long as the surrounding normal tissue is EGFR-negative. We have previously studied the therapeutic effects of CNR + NIR laser in HTB9 bladder human cancer cells \[[@ref011]\]. To expand on that work, the MB49 was used to study the efficacy of CNR treatment. MB49 cells represent a murine bladder cancer cell model, noting that the C-225 antibody is reactive in murine models and MB49 cell demonstrate EGFR expression. In [Fig. 1B](#blc-3-blc170096-g001){ref-type="fig"}, we see that with low levels of NIR laser application, there is no cellular killing, due to lack of thermal heating. With longer laser treatment duration, the cell death increases dramatically, but only in the cells treated in conjunction with CNR and not in those without CNR. There is no clear toxicity to CNR compared to the C-225 antibody alone.

Establishment of the orthotopic xenograft urinary bladder cancer model {#sec0065}
----------------------------------------------------------------------

T24 cells are tumorigenic \[[@ref014]\] and have relatively high expression of EGFR \[[@ref012]\]. Thus, we transfected T24 cells with luciferase and selected single clones for expansion and bladder implantation, [Fig. 2A and B](#blc-3-blc170096-g002){ref-type="fig"}. Bioluminescent imaging provided evidence for *in vivo* implantation and growth of bladder cancer cells in the nu/nu mice when assessed at day 7. Using the intravesical instillation technique described earlier, a tumor implantation rate of 90% was obtained in this model. [Figure 2C](#blc-3-blc170096-g002){ref-type="fig"} shows positive bioluminescent signal after two months of cell implantation indicating the persistence of viable tumor in this model, and with no evidence of metastases.

![Establishment of new orthotopic xenograft bladder cancer model. After transfection with Lenti-luc virus, the T24 cells were seeded into 96 well plate and single clones with positive Luciferase activity were selected ([Fig. 2A](#blc-3-blc170096-g002){ref-type="fig"}). These cells were cultured and Luciferase activity was further confirmed ([Fig. 2B](#blc-3-blc170096-g002){ref-type="fig"}). The cells were implanted intravesically into the mouse bladders and a 90% tumor implantation rate was observed. Mice with positive tumor growth at one week were followed for two months, demonstrating tumor implantation and persistence ([Fig. 2C](#blc-3-blc170096-g002){ref-type="fig"}). Representative pictures of mice at 2 days post laser treatment with the laser doses of 3.2 W/cm^2^ for 15 seconds (left), 3.2 W/cm2 for 30 seconds (middle) and 2.1 W/cm^2^ for 30 seconds (right) ([Fig. 2D](#blc-3-blc170096-g002){ref-type="fig"}). The mouse in the middle shows slight erythema and skin contraction in contrast to the other mice which show no evidence of skin changes.](blc-3-blc170096-g002){#blc-3-blc170096-g002}

Optimization of safe laser dose {#sec0070}
-------------------------------

Although it has been shown that photothermal ablation for urothelial carcinoma is effective *in vitro,* translating this approach into the *in vivo* setting has the risk of "bystander" toxicity from non-specific heating of neighboring urothelial tissue and also loss of efficacy from a "heat sink" effect of the surrounding tissues. Therefore, it was critical to determine a safe and effective laser dose *in vivo*. The laser power density and the duration of laser treatment determine the integrated energy dose delivered by the laser. In the first pilot trial of the dose setting experiments, we applied the same dose level (6.3 W/cm^2^) used in our *in vitro* experiments for a duration of 1 minute. We found that this *in vitro* dose was poorly tolerated and tested with lower doses of laser energy. As shown in [Fig. 2D](#blc-3-blc170096-g002){ref-type="fig"}, erythema and slight but permanent tissue contraction change was observed at the power density of 3.2 W/cm^2^ for 30 seconds, while no such changes were seen with 3.2 W/cm^2^ for 15 seconds or at the power density of 2.1 W/cm^2^ for 30 seconds. [Table 1](#blc-3-blc170096-t001){ref-type="table"} summarizes the optimization of NIR laser dose according to the appearance of erythema and skin change. Based on these findings, we determined the optimal dosing and subsequent treatments were made with a power density of 2.1 W/cm^2^ over 30 seconds.

###### 

Optimization of Laser Dose Treatment

  ---------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Power Density     1.0   1.0   1.3   1.3   2.1   2.1   3.2   3.2   4.2   4.2
  (W/cm^2^)                                                              
  Time (s)          30    45    15    30    30    45    15    30    15    30
  Erythema Score     0     1     0     3     0     1     0     2     3     3
  ---------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----

Skin toxicity was scored from 0 (no change) to 3 (erythema with chronic skin change) according to the degree of erythema.

Effect of photothermal treatment on cell expression of proliferative and apoptotic biomarkers {#sec0075}
---------------------------------------------------------------------------------------------

To minimize "heat sink" effect of urine, the bladder was drained of all urine before each treatment. We assessed the Ki67 and Cleaved-Caspase 3 expression by immunohistochemistry of the bladders after nanoparticle and laser treatment. Ki67 is known to be a proliferative biomarker associated with thermal tissue damage \[[@ref015]\] and has also been used to detect the effect of nanoparticle treatment \[[@ref017]\]. Cleaved caspase-3 has been used to discriminate between necrotic or apoptotic cell killing status after nanoparticle treatment \[[@ref018]\] and was also assessed. As shown in [Fig. 3](#blc-3-blc170096-g003){ref-type="fig"}, in the presence of CNR with the recommended dose laser treatment (2.1 W/cm^2^ for 30 seconds), a mild increase of expression of Ki67 and cleaved caspase 3 was noted in the urothelium of bladder as compared with two negative controls (laser without CNR and CNR without laser), consistent with a photothermal effect. In contrast, evaluation of the tissue from the initial experiments to optimize a safe laser dose, which produced some skin toxicity (3.2 W/cm^2^ power for 30 seconds, [Fig. 3A-IV](#blc-3-blc170096-g003){ref-type="fig"}) showed high levels of Ki67 expression in the underlying lamina propria of the urothelium, consistent with heat damage. Cleaved-caspase-3 staining ([Fig. 3B](#blc-3-blc170096-g003){ref-type="fig"}) showed no significant changes even after high dose laser treatment ([Fig. 3B-VIII](#blc-3-blc170096-g003){ref-type="fig"}). These results are consistent with previously reported values of Ki67 expression in cultured cells treated with nanorod-associated thermal ablation \[[@ref016]\].

![Proliferative and apoptosis cell signaling after CNR and photothermal treatment. One week after photothermal treatment, the mice were euthanized and bladders were excised and subjected to formalin fixing and paraffin-embedding. Immunohistochemical stains were performed as described in the Materials and Methods section. Ki67 staining ([Fig. 3A](#blc-3-blc170096-g003){ref-type="fig"}) shows an increase in nuclear expression in the bladder urothelium after treatment with the recommended laser treatment dose (power density of 2.1 W/cm^2^ for 30 seconds) ([Fig. 3A-III](#blc-3-blc170096-g003){ref-type="fig"}), while negative staining is observed in the bladder urothelium of mice from CNR only ([Fig. 3A-I](#blc-3-blc170096-g003){ref-type="fig"}), and laser only ([Fig. 3A-II](#blc-3-blc170096-g003){ref-type="fig"}) control treatments. Photothermal treatment at higher doses was associated with external skin toxicity (power density of 3.2 W/cm^2^ for 30 seconds) and showed an increase in the expression of Ki67, extending into the muscularis propria ([Fig. 3A-IV](#blc-3-blc170096-g003){ref-type="fig"}), consistent with a thermal treatment effect and skin changes at higher doses. Cleaved caspase-3 staining shows a similar pattern ([Fig. 3B, V, VI, VII](#blc-3-blc170096-g003){ref-type="fig"}) except that there was not a positive stain in the muscularis propria observed in the mouse with higher dose of photothermal treatment ([Fig. 3B-VIII](#blc-3-blc170096-g003){ref-type="fig"}).](blc-3-blc170096-g003){#blc-3-blc170096-g003}

Photothermal effect of gold nanorod conjugates on xenograft growth {#sec0080}
------------------------------------------------------------------

Mice were selected for photothermal treatment after confirmation of tumor implantation, based on the presence of bioluminescent activity 7 days after the cell instillation procedure. The experiment designed here utilized three intravesical control conditions: (1) laser alone, (2) laser with NNR and (3), laser with CNR. As shown in [Fig. 4A](#blc-3-blc170096-g004){ref-type="fig"}, laser plus CNR resulted in a significant reduction of luciferase activity, consistent with a therapeutic response. In contrast, the group of mice treated with laser alone had increasing bioluminescent tumor activity over time. Furthermore, CNR incubation without laser also resulted in tumor growth and persistence, but this condition was only tested in 2 mice in a demonstration fashion ([Fig. 4B](#blc-3-blc170096-g004){ref-type="fig"}). Quantification of the bioluminescence levels over 6 weeks is shown in [Fig. 4C](#blc-3-blc170096-g004){ref-type="fig"}. Significant changes were observed after 6 weeks of treatments (ANOVA F(2,32) = 3.43 *p* = 0.045). *Post hoc* tests showed that the laser plus CNR treatment (CNR+NIR light, *n* = 16) yielded lower bioluminescent activity compared to laser treatment alone (*n* = 14), Mean difference = 1045.8±400, *p* = 0.035. Furthermore, when comparing bioluminescence levels between pre-treatment and the six-week time points, mice treated with laser only showed significant increase in signal (mean difference = 520.6±233.15, *p* = 0.044). Conversely, mice treated with CNR+NIR light showed significantly lower bioluminescent activity compared to their corresponding pre-treatment levels (mean difference = --288.50±131.87, *p* = 0.045). The naked nanorods and laser treatment group (NNR+NIR light, *n* = 5) did not show statistical significant differences. Interestingly, no significant differences were also observed between the 6-week and pre-treatment time points for the NNR+NIR light group (*p* = 0.4), suggesting partial anti-tumor effect, but less activity than observed with the CNR + NIR light treatments.

![*In vivo* Photothermal effects of nanorods. Representative mice with positive luciferase images were intravesically treated with CNR in conjunction with external delivery of NIR light once per week for four weeks, using the optimized safe dose of laser treatment (power density of 2.1 W/cm^2^ for 30 seconds). The presence of viable tumor cells was tracked by bioluminescent imaging weekly for at least six weeks. Representative images show significant anti-tumor effect of CNR followed by NIR laser as compared with the negative controls with and without CNR followed by laser treatment ([Fig. 4A](#blc-3-blc170096-g004){ref-type="fig"}) and CNR treatment with and without laser ([Fig. 4B](#blc-3-blc170096-g004){ref-type="fig"}). [Figure 4C](#blc-3-blc170096-g004){ref-type="fig"} shows the effects of treatments on tumor growth by luminescence units. ^\*^*p* = 0.035 effect of CNR+Laser treatment compared to laser treatment alone at 6 weeks. ^\#^*p*≤0.04 and ^a^*p* = 0.046 compared to pre-treatment. NNR = naked nanorods, CNR = conjugated nanorods.](blc-3-blc170096-g004){#blc-3-blc170096-g004}

DISCUSSION {#sec0085}
==========

Thermal ablation mediated by gold nanorods has been proved to effectively kill cancer cells. More recent studies have shown that gold nanorods can be modified with specific tumor-targeting antibodies to enhance their specificity and efficacy for cancer therapy \[[@ref019]\]. In the current investigations, we have used EGFR-conjugated gold nanorods (CNR) and NIR laser therapy to specifically target orthotopic bladder xenografts in mice.

The primary outcome of our studies was the assessment of tumor bioluminescent activity over a 6-week treatment period, where CNR and laser combinatorial treatments were compared to laser treatments alone. Our studies are novel in that the delivery of the CNR was done by intravesicular instillation, allowing for the assessment of "bystander toxicity" effect in neighboring tissues and also for the "heat sink" effect of the *in vivo* environment, which would decrease efficacy. There are two main findings from our studies: 1) CNR plus NIR light showed a significant reduction in tumor compared to the NIR laser alone, and 2) This treatment is well tolerated *in vivo*, without substantial injury to the normal urothelium at the recommended dose. In fact, CNR treatment alone did not result in any decrease in tumor growth, underscoring the fact that there is no evidence that CNR treatment by itself is toxic to the cells. CNR treatment alone also did not show substantial tumor effect using *in vitro* models of bladder cancer in previous work \[[@ref011]\]. Laser treatment alone also did not block tumor growth over 6 weeks, which is consistent with the previously reported lack of cellular death after NIR laser treatments on cancer cells \[[@ref020]\].

An important concern with all classes of nanoparticles is their toxicity, which is determined by the dose, location and duration of confinement to the body. We have found that a single incubation of bladder xenografts with CNR alone did not increased the expression of cleaved-caspase 3, an apoptosis marker, suggesting that the CNR by themselves were not toxic to the tumor cells or the surrounding bladder tissue, consistent with what others have shown, \[[@ref018]\]. The addition of the laser treatment did increase the stains for cleaved-caspase 3, as this treatment likely initiates apoptotic events leading to decreased xenograft tumor growth. The positive expression of the proliferation marker Ki67 in the samples treated with CNR and higher laser power was expected, since it likely reflects a repair feedback response to the laser-induced heat accumulation in the tumor and surrounding muscle \[[@ref016]\]. However, despite these suggestive results, the mechanisms involved in the process of cell death mediated by CNR and laser treatments remain unresolved. Taken together, our findings show that this treatment is well tolerated and specific to the EGFR-expression tumor in this model.

It is important to note that the number of mice in our NNR + Laser treatment group was smaller (*n* = 5), compared to the main comparison cohorts (laser alone versus CNR + laser), thus hindering potential significant findings when comparing to laser treatments alone. It is possible that the NNR attached to the surface of the bladder tumor cells, without being internalized, resulted in photothermal damage after the laser treatments. In fact, other studies have shown that cancer cell death may occur in response to extracellular hyperthermia induced by gold nanorods \[[@ref021]\]. Without the guidance of an EGFR-directed moiety, the NNR may also be less effective due to a less robust association with the EGFR-expressing tumor. Our positive results with the EGFR-conjugated nanorods plus laser treatments are proof of concept that targeted delivery of CNR to the bladder tumor cells results in well-tolerated and effective therapy. In future studies, the relationship between EGFR expression and conjugate efficacy will need to be evaluated in a broader panel of human bladder cancer cell lines and xenografts to confirm the generalizability of these results and their association with EGFR expression. The luciferase imaging results will also need to be verified independently by other methods in addition to the luciferase-based assessments performed here.

In conclusion, we describe here for the first time the use of tumor-directed nanoparticles that generate thermal energy in response to NIR light exposure in conjunction with NIR light energy as a treatment for localized bladder cancer, using an orthotopic xenograft murine urinary bladder model. The results of this investigation reveal that photothermal treatment with EGFR-directed gold nanorods has important anti-tumor effects in the *in vivo* setting, without gross toxicity at the recommended treatment dose. These results suggest the possibility of a similar approach in the treatment of human bladder tumors, taking advantage of current cystoscopic means to deliver therapeutic NIR laser to nanorods can also be directly administered into the bladder via routine catheterization.
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